28th Annual Meeting of the ASGCT (13–17 May 2025)

We are proud to announce that our latest data on our Encapsulated Cell Therapy for Metachromatic Leukodystrophy (MLD) will be showcased at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place next week, 13–17 May, in New Orleans.

The presentation will be delivered by Dr. Françoise Piguet, Head of the GENOV Innovation Unit at the Paris Brain Institute and Release Therapeutics' strategic partner in the development of the Myo-P platform technology, during the Oral Abstract Session 'Gene and Cell Therapy for Metabolic Diseases’ on Tuesday, May 13, between 1:30 and 3:15 PM.

Focusing on the sustained delivery of Arylsulfatase A (ARSA) and therapeutic efficacy of the Myo-P4 demonstrated in large animal models, this presentation reflects our shared determination with the Paris Brain Institute to advance targeted, long-acting therapies for MLD and other CNS diseases through our platform. 

If you’re attending ASGCT, we invite you to join the session and connect with us to learn more about how we’re redefining what intracerebral cell-based therapies can do — for MLD and beyond.

The Release Tx Team